Evidence map›Paper›PMID 42894089›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Delayed diagnosis of cerebrotendinous xanthomatosis with progressive neurological involvement: a case report.

Wenting Zhou, Yanyun Wu, Sihui Chen, Youjia Liu, Wei Song, Huifang Shang, Chen Xueping, Ruwei Ou

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenting Zhou *Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Yanyun Wu *Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Sihui ChenDepartment of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Youjia LiuDepartment of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Wei SongDepartment of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Huifang ShangDepartment of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Chen XuepingDepartment of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Ruwei OuDepartment of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. ouruwei@aliyun.com.ORCID http://orcid.org/0000-0002-9971-6185

Funding

National Natural Science Foundation of China No. 82271272
6 · The paper itself

Abstract

backgroundCerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive metabolic disorder caused by pathogenic variants in the CYP27A1 gene. Although effective treatment with chenodeoxycholic acid (CDCA) is available, diagnosis is often delayed due to its heterogeneous clinical manifestations and involvement of multiple organ systems. CASE: We report a 34-year-old man with genetically confirmed CTX who presented with progressive gait instability, dysarthria, dysphagia, and cognitive impairment. His medical history revealed childhood-onset bilateral cataracts, chronic diarrhea, and poor academic performance, while bilateral Achilles tendon masses that developed in adulthood were initially misdiagnosed as benign lipomas. Neurological examination demonstrated cognitive impairment, cerebellar ataxia, and pyramidal signs. Whole-exome sequencing identified a homozygous pathogenic variant in CYP27A1 (NM_000784.4): c.1072 C > T; p.(Gln358Ter), confirming the diagnosis of CTX. After initiation of CDCA therapy (750 mg/day), plasma 7α-hydroxy-4-cholesten-3-one levels decreased markedly, accompanied by improvements in gastrointestinal symptoms, cognition, gait stability, and daily living activities during 6 months of follow-up. However, persistent cerebellar atrophy on follow-up neuroimaging suggested limited reversibility of established neurological damage.

conclusionThis case highlights the importance of recognizing multisystem manifestations of CTX for early diagnosis and timely CDCA therapy.

Indexed as

Delayed DiagnosisXanthomatosis, CerebrotendinousAdultChenodeoxycholic AcidCholestanetriol 26-MonooxygenaseDisease ProgressionHumansMaleChenodeoxycholic AcidCholestanetriol 26-MonooxygenaseCYP27A1 protein, humanAchilles tendon xanthomaCerebrotendinous xanthomatosisChenodeoxycholic acidCYP27A1Diagnostic delay

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.